Galenica AG (GALE) Fair Value & Analysis
Healthcare · CH · Market cap CHF 4.3B
Fair value as of: Aug 13, 2026
From 25 valuation models · updated yesterday
Share price −7.0% over the past month.
A solid business, but screening 24% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (CHF 77.24). The favourable scenario is already priced in.
- Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range CHF 57.79 – CHF 101.34 · fair‑value band CHF 46.34 – CHF 77.24 · the CHF 81.10 price screens above the CHF 61.79 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Galenica AG (GALE) currently trades at CHF 81.10, while our model-based Fair Value estimate is CHF 61.79, implying the stock looks roughly 23.8% overvalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Galenica AG generated revenue of CHF 4.1B at a net margin of 4.4%. Revenue grew 5.8% year over year. It earns a return on equity of 12.1%. Net debt stands at CHF 945M. Fundamentals as of Aug 13, 2026
Our scenario range runs from CHF 46.34 (bear case) to CHF 77.24 (bull case); at CHF 81.10, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 20% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 33% fair-value upside, at -24%, GALE screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: DCF Models (CHF 67.99) versus Asset-Based (CHF 19.93). Highest evidence: Growth DCF (80).
Notify me when GALE reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 60 · Market factors (momentum, volatility) 48
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Galenica AG provides healthcare services in Switzerland and internationally. It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates and manages pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands, as well as covers specialty pharmacy mediservice.
Full company description
Galenica AG provides healthcare services in Switzerland and internationally. It operates through two segments, Products & Care, and Logistics & IT. The Products & Care segment operates and manages pharmacies and partner pharmacies under the Amavita, Sun Store, and Coop Vitality brands, as well as covers specialty pharmacy mediservice. This segment also offers medication for treatment of patients at home; laboratory medicine, pathology and specialized personalized diagnostic services; and develops, markets, and sells healthcare services and products through various distribution channels. The Logistics & IT segment provides various specialized pre-wholesale services, including storage, distribution, and debt collection to pharmaceutical and healthcare companies. This segment also offers master data systems for the healthcare market; develops management solutions for the healthcare market; and publishes printed and electronic technical information on pharmaceutical products, as well as offers complete management solutions for pharmacies. In addition, it provides on-schedule delivery services to pharmacies, drugstores, doctors, hospitals, and care homes. The company was founded in 1927 and is headquartered in Bern, Switzerland.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Galenica AG reported revenue of CHF 4.1B in FY2025 versus CHF 3.8B in FY2021, a compound +1.9%/yr. Reported net income was CHF 181M in FY2025, compounding +1.9%/yr from FY2021.
of which total revenue +3.4 pp · buybacks/dilution +0.0 pp
Absolute contributions in percentage points per year; they sum to the EPS growth rate. Start and end points are 3-year averages (details on hover).
GALE screens 24% overvalued. Compare with McKesson Corporation →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Galenica Ltd (WBO:GALE) (H1 2026) Earnings Call Highlights: Strong Core Growth and Strategic ...
- Galenica AG (VTX:GALE) Shares Could Be 33% Below Their Intrinsic Value Estimate
- Institutions own 45% of Galenica AG (VTX:GALE) shares but retail investors control 55% of the company
- Galenica AG's (VTX:GALE) Stock Has Shown A Decent Performance: Have Financials A Role To Play?
Peer Group
Medical Distribution · 77 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Distribution median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Distribution stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| McKesson Corporation MCK | $878.73 | $819.31 | -7% |
| Cencora, Inc COR | $314.17 | $211.07 | -33% |
| Cardinal Health, Inc CAH | $234.16 | $141.77 | -39% |
| Henry Schein, Inc HSIC | $90.74 | $71.70 | -21% |
| Shanghai Pharmaceuticals Holding 601607 | ¥16.56 | ¥33.96 | +105% |
| Sinopharm Group 1099 | HK$16.75 | HK$58.67 | +250% |
| Guangzhou Baiyunshan Pharmaceutical Holdings 600332 | ¥21.49 | ¥28.65 | +33% |
| Jointown Pharmaceutical Group 600998 | ¥5.04 | ¥9.84 | +95% |
| Asker Healthcare Group ASKER | kr 80.00 | kr 28.26 | -65% |
| China National Medicines Corporation 600511 | ¥27.35 | ¥58.22 | +113% |
Compare Galenica AG with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Galenica AG (GALE) overvalued or undervalued?
What is the fair value of GALE?
What is the quality score of GALE?
What is the revenue of Galenica AG (GALE)?
What is the net profit margin of GALE?
Does Galenica AG pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Galenica AG and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.